According to WHO, in week 23, 2026 (1st June to 7th June): 17 out of 26 countries of the enhanced meningitis surveillance network shared their meningitis epidemiological data.
Epidemics (incidence ≥ 10/100’000 inhabitants):
Alerts (incidence ≥ 3 and <10/100’000 inhabitants):
For previous epidemics and alerts, see news at www.healthytravel.ch.
Vaccination with a quadrivalent meningococcal conjugate vaccine (Menveo® or Menquadfi®) is recommended as follows:
Guatemala: Since the outbreak began in January 2026, Guatemala has reported 16,840 measles cases (6,903 laboratory-confirmed) and 22 deaths, up from 10 deaths in mid-May. Most fatalities occurred in young children, including three infants too young to be vaccinated.
Guatemala Department accounts for nearly half of confirmed cases, with Guatemala City reporting over 2,100 infections. Weekly cases peaked in March and have since declined substantially.
The outbreak was linked to a large international religious gathering in December 2025. More than 1.1 million vaccine doses have been administered, and mass vaccination campaigns are being expanded to affected departments.
Honduras: As of 12 June 2026, Honduras has confirmed five measles cases: four imported from Guatemala and one locally acquired case in an unvaccinated 25-year-old woman on Roatán, marking the country's first autochthonous measles case since elimination in 1997.
In response, health authorities have launched contact tracing, expanded vaccination campaigns, mandated mask use in health facilities, and extended the national immunization campaign through 30 June. Vaccination coverage remains below the 95% target.
Measles outbreaks are increasing worldwide.
Measles spread quickly and can be dangerous - protection is simple: get vaccinated!
Swiss recommendations: All persons born after 1963 who have no documented protection against the infection (antibodies or 2 documented vaccinations) should be vaccinated twice with MMR vaccine at one month interval. In the event of an epidemic in the region or contact with a measles case, vaccination is recommended from the age of 6 months.
As of 13 June 2026, Malaysia reported 33'367 dengue cases, a 27% increase compared with the same period in 2025. The highest burden was recorded in Selangor (15'422 cases), followed by Kuala Lumpur/Putrajaya (6'107) and Johor (3'556). Sabah experienced the sharpest rise, with cases increasing by 50% to 2'866. Twenty-three deaths were reported, up from 17 during the same period last year.
Health authorities attribute the increase to the expected cyclical dengue pattern and the emergence of DENV-3 as the dominant serotype. In response, the Ministry of Health has strengthened prevention efforts through its Dengue-Free Community (Kombat) program.
Prevention: Optimal protection against mosquitoes 24/7, including against other mosquito-borne diseases.
Vaccination: The Swiss Committee of Experts in Travel Medicine (ECMV) recommends vaccination with Qdenga® only for travellers over 6 years of age who have already contracted dengue; see the ECTM statement.
In case of fever:
EU/EEA and outermost territories
In April 2026, 29 EU/EEA countries reported measles data: 17 countries reported 451 cases and 12 reported none. The highest numbers were reported in Bulgaria (163), Italy (133), Latvia (38), France (32), and Spain (23).
Between 1 May 2025 and 30 April 2026, 30 EU/EEA countries reported 3’779 measles cases, of which 84% were laboratory confirmed. Children under five years accounted for 34% of cases, while adults aged ≥15 years represented 44%. The highest notification rates were observed among infants under one year and children aged 1–4 years.
Among cases with known vaccination status, 78% were unvaccinated, 12% had received one dose, and 9% had received two or more doses of a measles-containing vaccine. Three measles-related deaths were reported during the period, including two in France and one in the Netherlands.
Outbreaks continue in Bulgaria, while sporadic cases and clusters have been reported across several other EU/EEA countries.
Europe outside EU/EEA
Ukraine: Since the beginning of the year and as of April 2026, there has been 201 cases.
UK: Between 1 January and 8 June 2026, England reported 736 laboratory-confirmed measles cases, including 106 cases in the previous two weeks, compared with 959 cases during all of 2025. Two measles-related deaths in children were confirmed, the first such deaths in England and Wales since 2018. Children aged ≤10 years accounted for 61% of cases, while London reported over half of all infections (404 cases). Despite ongoing transmission, MMR coverage remains below the 95% target, with first-dose coverage at 91.8% and second-dose coverage at 83.9% nationally.
Measles outbreaks are increasing worldwide.
Measles spread quickly and can be dangerous - protection is simple: get vaccinated!
Swiss recommendations: All persons born after 1963 who have no documented protection against the infection (antibodies or 2 documented vaccinations) should be vaccinated twice with MMR vaccine at one month interval. In the event of an epidemic in the region or contact with a measles case, vaccination is recommended from the age of 6 months.
The Democratic Republic of the Congo's (DRC) 17th Ebola outbreak, caused by the Bundibugyo virus and declared a Public Health Emergency of International Concern (PHEIC) on 17 May 2026, has been spreading across the provinces of Ituri, North Kivu, and South Kivu, with confirmed cross-border transmission into the Ugandan capital, Kampala.
Critical containment gaps, including insecurity and conflict, a contact follow-up rate well below the target level, infections among healthcare workers, deficiencies in infection prevention and control (IPC), and a funding shortfall, are sustaining transmission. The absence of an approved vaccine for this species of ebolavirus limits the range of available countermeasures.
On 2 June 2026, WHO reported that the number of suspected cases in the DRC had decreased compared to previous reports after many were ruled out through investigation and testing. This decline reflects case reclassification rather than necessarily reduced transmission.
D.R. Congo: data as of 04 June 2026 (for updates see WHO dashboard and ECDC):
Uganda: data as of 04 June 2026 (for updates see WHO dashboard and ECDC):
Outside Africa:
Entry and exit screenings and control measures:
Authorities are concerned about the risk of further spread due to population high mobility, insecurity, and the proximity of affected areas to Uganda and South Sudan through a porous border.
Distribution of suspected and confirmed Bundibugyo virus disease cases in the Democratic Republic of the Congo and Uganda, as of 6 June 2026:
WHO assesses the risk of the epidemic as very high at the national level, high at regional levels, and low at the global level (including Switzerland and the EU/EEW). For details, see LINK.
ECDC assesses the risk for EU/EEA travellers in affected areas as low if precautions (see under “consequences for travelers”) are followed but emphasizes uncertainties and rapid evolution.
Due to the very recent declaration of the outbreak and the uncertainties related to the
epidemiological information, it is probable that the outbreak is much larger than what is currently
being reported – not only in regards to the number of affected cases, but also in its geographical extent.
The situation is evolving rapidly! Always stay informed before, during, and after travel! As of 11 June 2026:
The following precautions are recommended for all travel to the DRC and Uganda as well as in neighboring countries:
General preventive measures:
Of note: there is currently no licensed vaccine or specific treatment against Ebola diseased caused by Bundibugyo virus. For humanitarian missions, consultation with a travel medicine specialist is recommended.
While in the affected areas in DRC and in Uganda and for 21 days after leaving:
! In case of symptoms headache, body aches, muscle pain, fatigue, loss of appetite, vomiting or diarrhea during your stay in and for 21 days after leaving north-eastern D.R. Congo (province of Ituri, North Kivu, South Kivu) and /or Uganda, especially the affected areas:
Recommendations of the Swiss Expert Committee for Travel Medicine (as of 11 June 2026, subject to change according to the evolving situation):
A suspected case is:
Such cases should be isolated, tested, and reported to the Cantonal Physician and the Swiss Federal Office of Public Health within 2 hours.
*High-risk exposure includes:
Between January and mid-April 2026, Zimbabwe reported 65’399 malaria cases and 174 deaths, nearly double the number of cases reported during the same period in 2025 (around 36'000) and almost four times the 2024 total (around 17’000). The outbreak has affected multiple districts across Manicaland, Mashonaland Central, Mashonaland East, and Mashonaland West, including areas previously nearing elimination.
Similar increases are being observed across other countries in Southern Africa Region. The surge has been linked to heavy rainfall during the 2025–2026 season, which created favorable mosquito-breeding.
Meteorological forecasts predict increased rainfall across southern African countries in the upcoming months. Given the already high malaria case numbers from January to May 2026 in Namibia, Botswana, and Zimbabwe, it is possible that these countries will face heightened malaria risk from June to August, even in areas where risk is typically moderate during these months.
Optimal mosquito protection 24/7 (at dusk and at night against malaria, during the day against other arboviruses).
Malaria chemoprophylaxis is recommended, including during the usually moderate transmission period from June to August in seasonal risk areas, given the recent increase in malaria cases and the forecasted increased precipitations in the upcoming months and favorable conditions for mosquito breeding.
0
